澳门新葡亰网站注册

欢迎访问澳门新葡亰网站_官方登录注册

陈毅歆副教授博导

发布时间:2015-10-24来源:点击数:5393

 

陈毅歆,CHEN YixinPh.D. 

副教授,博士生导师

国家传染病诊断试剂与疫苗工程

技术研究中心单抗组组长

办公室:厦门大学翔安校区椭圆楼321室

电话:+86-592-2181661

E-mail: yxchen2008@xmu.edu.cn

 

1999,福州大学生工系,学士

2005澳门新葡亰网站注册,硕士

2008,澳门新葡亰网站注册,博士

2009,澳门新葡亰网站注册,助理教授

2014,澳门新葡亰网站注册,副教授

1999, B.Sc., Dept. of Biological Engineering, Fuzhou University

2005, M.Sc., School of Life Sciences, Xiamen University

2008, Ph.D., School of Life Sciences, Xiamen University

2009, Assistant Professor, School of Life Sciences, Xiamen University

2014, Associate Professor, School of Life Sciences, Xiamen University

 

研究领域(Research Area)

本课题组主要涉及两个领域的研究:其一,从事流感、中东呼吸综合症、手足口病、病毒性肝炎和疱疹病毒相关疾病等病毒性传染病的基础研究与应用转化研究,主要依托成熟的小鼠、大鼠、兔和鸡禽等单克隆抗体技术平台筛选出识别新型病毒靶标/表位的功能性抗体,以引导预防性疫苗、治疗性药物和诊断试剂盒的研发。其二,从事肿瘤诊治领域研究,基于“以毒攻毒”的策略,将某些病毒通过遗传改造发展成新型溶瘤病毒,用于癌症的治疗;基于功能抗体的正向筛选技术发现新型肿瘤特异性靶标,以引导新型肿瘤治疗性抗体药物和肿瘤特异诊断方法的研发。

Our research focuses on two major areas: One is the basic, applied and translational researches for understand and control of infectious diseases such as influenza, MERS, HFMD, viral hepatitis, herpesvirus associated disease. Functional monoclonal antibodies targeting novel epitopes of viruses were identified using mouse, rat, rabbit, and chicken antibody techniques. Such epitopes and antibodies can be used as promising candidates for the development of vaccines, therapeutic agents, and diagnostic kits against specific viruses. The other is the cancer research, including the development of oncolytic virus for cancer therapy and the discovery of novel tumor targets for cancer diagnosis and therapy.


 

代表性论文(Selected Publications)# Co-first author* Corresponding author)

1.     Shen C, Zhang M, Chen Y, Zhang L, Wang G, Chen J, Chen S, Li Z, Wei F, Chen J, Yang K, Guo S, Wang Y, Zheng Q, Yu H, Luo W, Zhang J, Chen H, Chen Y*, Xia N. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics. 2019 Jan 1;9(1):210-231.

2.     Chen J, Yang K, Zhang M*, Shen C, Chen J, Wang G, Huang S, Zhang M, Xiong H, Chen H, Chen Y*, Xia N. Rapid identification of imported influenza viruses at Xiamen International Airport via an active surveillance program. Clinical Microbiology and Infection, 2018 Mar;24(3):289-294. 

3.     Woo PCY #, Lau SKP #, Chen Y#, Wong EYM, Chan KH, Chen H, Zhang L, Xia N, Yuen KY. Rapid detection of MERS coronavirus-like viruses in bats: potential for tracking MERS coronavirus transmission and animal origin. Emerging Microbes & Infections. 2018 Mar 7;7(1):18.

4.     Lin Q #, Li T #, Chen Y #, Lau SY, Wei M, Zhang Y, Zhang Z, Yao Q, Li J, Li Z, Wang D, Zheng Q, Yu H, Gu Y, Zhang J, Chen H, Li S, Xia N. Structural Basis for the Broad, Antibody-Mediated Neutralization of H5N1 Influenza Virus. Journal of Virology. 2018 Aug 16;92(17).

5.     Shen C, Chen J, Li R, Zhang M, Wang G, Stegalkina S, Zhang L, Chen J, Cao J, Bi X, Anderson SF, Alefantis T, Zhang M, Cai X, Yang K, Zheng Q, Fang M, Yu H, Luo W, Zheng Z, Yuan Q, Zhang J, Wai-Kuo Shih J, Kleanthous H, Chen H, Chen Y*, Xia N*. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science Translational Medicine. 2017 Oct 18;9(412). (Peter Palese comments in Nature, Highlighted by Nature Reviews Drug Discovery, Highlighted by “常识分子”)

6.     Chen Y, Chan KH, Hong C, Kang Y, Ge S, Chen H, Wong EY, Joseph S, Patteril NG, Wernery U, Xia N, Lau SK, Woo PC. A highly specific rapid antigen detection assay for on-site diagnosis of MERS. Journal of Infection. 2016 Jul;73(1):82-4.

7.     Zhang P #, Chen Y#, Zeng Y #, Shen C, Li R, Guo Z, Li S, Zheng Q, Chu C, Wang Z, Zheng Z, Tian R, Ge S, Zhang X, Xia NS, Liu G, Chen X. Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6129-38.

8.     Chen Y, Chan KH, Kang Y, Chen H, Luk HK, Poon RW, Chan JF, Yuen KY, Xia N, Lau SK, Woo PC. A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus. Emerging Microbes & Infections. 2015 Apr;4(4):e26. (Highlighted by Nature.com)

9.     Gui X, Li R, Zhang X, Shen C, Yu H, Guo X, Kang Y, Chen J, Chen H, Chen Y*, Xia N*. An important amino acid in nucleoprotein contributes to influenza A virus replication by interacting with polymerase PB2. Virology,2014,464-465:11-20.

10.     Gui X, Ge P, Wang X, Yang K, Yu H, Zhao Q, Chen Y*, Xia N*. Identification of a highly conserved and surface exposed B-cell epitope on the nucleoprotein of influenza A virus. Journal of Medical Virology,2014,86:995-1002.

11.     Chen Y #, Li C #, He D, Cheng T, Ge S, Shih JW, Zhao Q, Chen P-J, Zhang J, Xia N. Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: Current genotyping of EV71 does not reflect their antigenicity. Vaccine,2013,31:425-30.

12.     Wu WL, Lau SY, Chen Y, Wang G, Mok BW, Wen X, Wang P, Song W, Lin T, Chan KH, Yuen KY, Chen H. The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses. Antiviral Research,2012,93:144-153.

13.     Chen Y #, Zheng Q#, Yang K, Zen F, Lau S-Y, Wu WL, Huang S, Zhang J, Chen H, Xia N. Serological survey of antibodies to influenza A viruses on a group of people without a history of influenza vaccination.Clinical Microbiology and Infection,2011,17:1347-1349.

14.     Zheng Q, Xia L, Wu WL, Zheng Z, Huo Y, Wu J, Liu Y, Yu H, Chen Y, Lau SY, Chen H, Luo W, Xia N. Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses. Antimicrobial Agents and Chemotherapy,2011,55:1349-1357.

15.     Chen Y, Xu F, Gui X, Yang K, Wu X, Zheng Q, Ge S, Yuan Q, Yeo AET, Zhang J, Guan Y, Chen H, Xia N. A rapid test for the detection of influenza A virus including pandemic influenza A/H1N1 2009.Journal of Virological Methods, 2009,167:100-102.

16.     Chen Y #, Qin K#, Wu WL, Li G, Zhang J, Du H, Ng MH, Shih JWK, Peiris JSM, Guan Y, Chen H, and Xia N. Broad Cross-Protection against H5N1 Avian Influenza Virus Infection by Means of Monoclonal Antibodies that Map to Conserved Viral Epitopes.Journal of Infectious Diseases,2009,199:49-58.

17.     WL Wu#Chen Y #, Wang P, Song W, Lau SY, Rayner JM, Smith GJD, Webster RG, Peiris JSM, Lin T, Xia N, Guan Y and Chen H. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007.Journal of Virology, 2008,82:1798-1807.

18.  Chen Y, F Xu, X Fan, H Luo, S Ge, Q Zheng, N Xia, H Chen, Y Guan, and J Zhang. Evaluation of a rapid test for detection of H5N1 avian influenza virus. Journal of Virological Methods,2008,154:213-215.



 

授权发明专利 (Patents)

(1)Chen Yixin, Shen Chenguang, Chen Junyu, Wang Guosong, Zhang Mengya, Xia Ningshao. Broad-spectrum monoclonal anti-flu B antibody and uses thereof. Australian Patent No.: 2016270147, 2018.12.06

(2)陈毅歆,桂勋,吴兴容,黄德党,郑清炳,夏宁邵。甲型流感病毒核衣壳蛋白的抗原表位及其用途。中国发明专利号:ZL201110122466.5,2018.2.9 

(3)程通,徐龙发,杨立生,陈毅歆,杜海莲,张军,夏宁邵。肠道病毒71 型的VP2 抗原的中和表位多肽及其用途。中国发明专利号:ZL201510106427.4, 2018.5.4 

(4)Yixin Chen, Qingbing Zheng, Rui Li, Chenguang Shen, Shaojun Ke, Wenxin Luo, Honglin Chen, Ningshao Xia. Broad-spectrum monoclonal antibody recognizing HA1 domain of hemagglutinin of influenza virus. United States Patent no.: US9650434B2, 2017.5.16

(5)Yuan Quan, Zhang Tianying, Luo Wenxin, Chen Yixin, Zhang Jun, Xia Ningshao. Poly-peptides and antibodies for treating HBV infection and related diseases. United States Patent No.:US9751914B2, 2017.9.5

(6)罗文新,霍永庭,李善伟,崔传佳,陈毅歆,夏宁邵。特异结合高致病性禽流感病毒的抗体。中国发明专利号:ZL201210190369.4,2017.9.8

(7)Chen Yixin,Luo Wenxin,Zhang Jun,Xia Ningshao,Guan Yi,Chen Honglin. Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof (8G9), European Patent No.: EP2716656B1,2016.10.12

(8)Yixin Chen,Wenxin Luo,Jun Zhang,Ningshao Xia,Yi Guan,Honglin Chen. Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof (13D4), European Patent No.: EP2174957A1,2016.3.16

(9)葛胜祥,徐飞海,翁祖星,程通,何德磊,陈毅歆,陈自敏,夏宁邵。肠道病毒71型的中和表位多肽及其用途。中国发明专利号:ZL201110357994.9,2015.4.8

(10)陈毅歆,罗文新,张军,夏宁邵,陈鸿霖,管轶。H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途(8G9)。中国发明专利号:ZL201310131000.0,2015.1.21

(11)罗文新,陈毅歆,宋慧娟, 陈瑛炜,陈鸿霖, 张军,夏宁邵。H5亚型禽流感病毒保守中和表位模拟肽及其用途。中国发明专利号:ZL200910225192.5,2015.1.14

(12)罗文新,陈毅歆,郑振华,李国强, 陈鸿霖, 张军,夏宁邵。H5亚型禽流感病毒血凝素蛋白的人源化抗体及其用途。中国发明专利号:ZL200910179075.X,2015.1.7

(13)Chen Yixin, Luo Wenxin, Zhang Jun, Xia Ningshao, Guan Yi, Chen Honglin. Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof (13D4). United States Patent No.: US8603467B2, 2013.12.10

(14)陈毅歆,罗文新,张军,夏宁邵,管轶,陈鸿霖. 特异性结合H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途 (13D4). 中国发明专利号:ZL200810110869.6,2013.5.1

(15)罗文新,陈瑛炜,王明桥,陈毅歆,张军,夏宁邵。H5亚型禽流感病毒中和表位模拟肽及其用途。中国发明专利号:ZL 200810133705.5,2013.7.3

(16)夏宁邵,张军,葛胜祥,陈毅歆,罗文新。一种H5亚型禽流感病毒血凝素蛋白的单克隆抗体,其制备方法及其用途。中国发明专利号:ZL 200510007308.X,2009.4.1




奖励(Honors and Awards

(1)2017年福建省科技进步二等奖(排名第一),流感广谱表位的发现及流感抗原免疫诊断试剂的研制与应用

(2)2017年厦门市科技进步二等奖(排名第一),流感系列免疫诊断试剂的研发与应用

(3)2015 求是杰出科技成就集体奖,原核表达类病毒颗粒疫苗研究团队

(4)2014福建省科技进步奖一等奖(排名第三),手足口病系列免疫诊断试剂的研究与应用

(5)2014厦门市科技进步奖二等奖(排名第三),手足口病系列免疫诊断试剂的研究与应用

(6)2014厦门市科技进步奖三等奖(排名第八),口岸适用性甲型流感监测技术创新研究与应用

(7)2003北京市科技进步三等奖(排名第六),人类免疫缺陷病毒(HIV)抗体快速诊断试剂的研制



主持项目 (Grants)

(1)国家自然科学基金,甲型流感病毒血凝素头部区跨亚型广谱中和抗体的作用机制研究(81871651)2019-2022

(2)国家重点研究计划,重要突发急性和烈性传染病临床生物安全关键设备创制(2018YFC1200100)2018-2021

(3)国家自然科学基金,基于广谱中和单抗的通用型流感疫苗设计及其结构基础研究(31670934)2017-2020

(4)国家自然科学基金,人肠道病毒71型构象性中和表位的确定及其诱导抗病毒免疫保护应答机制研究(81371817)2014-2017

(5)法国赛诺菲巴斯德企业研究合约,通用型流感疫苗—鉴定针对季节性流感病毒的交叉中和性单克隆抗体的合作研究计划,2013-2017

(6)新药创制国家重大专项,H5N1禽流感病毒广谱治疗性单克隆抗体临床前研究(2011ZX09102-009-12)2011-2017

(7)福建省科技重大专项,系列肿瘤相关免疫诊断试剂高活性的关键原料的研制及产业化(2011YZ0002-1)2011-2016

(8)国家863计划子课题,抗体研发关键技术及产品研发(2012AA02A307)2012-2016

(9)厦门市科技项目,H5N1禽流感病毒广谱治疗性单克隆抗体临床前研究(3502Z20127027)2012-2013

(10)国家自然科学基金,H5N1禽流感病毒血凝素广谱中和表位的结构研究(30901077)2010-2012





XML 地图 | Sitemap 地图